Skye Salud, an AI-powered medical evidence platform developed by Brand Engagement Network, Grupo Skye, and KNOBLOCH Information Group, has moved to Phase 2 of clinical evaluation in Mexico. Following successful Phase 1 rheumatology testing, the platform will now be tested in primary care settings to assess its performance across a wider range of clinical topics using Spanish-language content tailored for Mexico. This expansion aims to improve access to trusted medical information and guide future development and commercialization in Latin America's large healthcare market. The initiative highlights the collaboration's focus on accuracy, transparency, and evidence-based AI solutions for healthcare.
The FDA extended its review of Exelixis' cancer drug zanzalintinib by three months without revealing any new clinical failures or safety concerns. This delay reduces the drug's present value by about 2.35%, which is less than the initial market loss....
Bitcoin is trading around $77,327 with minor daily gains but a weekly drop over 3%, facing resistance between $77,100 and $80,200 where long-term holders have sold significant amounts. CryptoQuant highlights $81,700 as a key level to confirm a new bu...
Spot Bitcoin ETFs experienced $462.7 million in net outflows from September 8 to 11, reversing nearly half of the previous week's inflows. This shift coincides with markets pricing in an 87% chance of a 25-basis-point rate hike at the upcoming Septem...
Visa reported better-than-expected Q3 results, with net revenue up 14%, earnings per share rising 11%, and free cash flow reaching about $6.14 billion. The company is expanding its value-added services and forming strategic partnerships to diversify ...
Tom Lee, co-founder of Fundstrat, states that Ethereum is becoming the key settlement layer for Wall Street and artificial intelligence (AI) applications. Despite a broader crypto market pullback, Ethereum has outperformed most major cryptocurrencies...
